Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Prospect Capital Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Prospect Capital Corporation trades at $2.25 (market cap $1.13B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 35.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.17% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PSEC | |
|---|---|---|
Market Cap | $39.89B | $1.13B |
Sector | Health | Financials |
52-Week High | $491.22 | $3.47 |
52-Week Low | $278.09 | $2.15 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 22.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PSEC trades at $2.26, up 2.26% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.38 and has beaten EPS estimates for three consecutive quarters. Recent news includes a new investment in ShipOffers and the sale of Valley Electric generating $328 million. Dividend payments continue at $0.04-$0.05 monthly, supporting income appeal despite negative revenue and net income in 2025.
Outlook remains cautious due to persistent negative profitability and revenue volatility, though deep discount to NAV and high yield may attract income investors. Key risks include declining NAV, portfolio quality concerns, and analyst skepticism. Upside depends on stabilization of investment income and successful execution of senior lending strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
